2 results about "Interferon beta" patented technology

Disclosed herein are engineered, non-naturally occurring protein variants with de novo glycosylation sites having wildtype-like biological activity of wildtype interferon beta. Also disclosed herein are vectors encoding the non-naturally occurring protein variants described herein. Also disclosed herein are pharmaceutical compositions comprising the non-naturally occurring protein variants described herein or a vector encoding the non-naturally occurring protein variants described herein. Also disclosed herein are methods of treating a disease by administering to a subject the non-naturally occurring protein variants described herein, a vector encoding the non-naturally occurring protein variants described herein, or a pharmaceutical composition comprising the non-naturally occurring protein variants described herein or a vector described herein.

This invention provides methods for treating acute respiratory distress syndrome (ARDS), including ARDS associated with respiratory viral infections. [Solution] Administer plasma kallikrein (pKal) inhibitors such as anti-pKal antibodies as inhibitors of the contact activation pathway. Immunomodulators such as IL-6R inhibitors, antiviral agents such as lopinavir, ritonavir, interferon beta, umfenovir, and remdesivir, antimalarial agents such as chloroquine, and / or inhibitors of the contact activation pathway such as C1 inhibitors, pKal inhibitors, and bradykinin receptor antagonists may be administered to the patient as additional therapeutic agents.